Position
Renaissance Technologies in Aligos Therapeutics, Inc.
Back to the book · All holders of ALGS
Estimated mark uses implied 13F prices (value ÷ shares). Adds are treated as happening at this quarter’s mark; cuts at last quarter’s. Share jumps can be splits, not buys. This is not realized P&L.
Latest estimated mark −$17.9K$7.43 → $5.77
| Quarter | Shares | Value | Implied px | Est. mark | Flow | Weight |
|---|---|---|---|---|---|---|
| Q4 2025 | 85.4K | $796.3K | — | — | — | 0.0% |
| Q1 2026 | 100.5K | $746.3K | $7.43 | −$161.5K | $111.5K | 0.0% |
| Q2 2026 | 10.8K | $62.3K | $5.77 | −$17.9K | −$666.1K | 0.0% |